PDCD1 and acral lentiginous melanoma: Among the 136 stage III patients with acral melanoma, the treatment of PD-1 inhibitor was still longer than the IFN+OBS groups (p = 0.05) (Figure 5B), while no significance was observed between the PD-1 and the IFN groups (p = 0.075) (Figure S5).